Overall verdict
Buy
6.6/10
1-year performance
+70.72%
Score breakdown
Up 70.7% over 1 year, 49% of the 52-week range.
Strongest: Profitability 9.6/10. Weakest: Shareholder return 3.6/10.
21 analysts, target +0.2% vs the price.
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation ; whole-genome sequencing kits, which sequence entire genomes of various size and complexity ;
and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.
The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem ; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research.
It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Sector
Health Care
Industry
Life Sciences Tools and Services
Primary listing
Nasdaq
United States
CEO
Jacob Thaysen
Founded
1998
Employees
8 600
Revenue / employee
504 419 USD
Next earnings
February 5, 2027 (estimated)
Institutional holders
- FMR LLC10.71%
- GEODE CAPITAL MANAGEMENT, LLC2.79%
- Bank of New York Mellon Corp1.14%
- Rest of the register85.36%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
309.35 USD
52-week low
112.65 USD
1-year performance
70.72%
Rising
Year-to-date performance
59.62%
Rising
Drawdown
-32.23%
Major drawdown
Position in the 52-week range
49% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned much more, but shaking 3.7 times harder: once that risk is counted, it did about as well as the ETF.
$10,000 placed at the end of December 2000 are worth today
| Illumina | $302,356 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 3.7 times as much as the world ETF.
- Worst fall:-91 % between January 2001 and April 2003. $10,000 placed at the top fell to $948. The world ETF, at worst: -53 %. Back to its high in 33 months.
Illumina earned 5 times as much as the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- Illumina: $302,356
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Based on past performance. This is not a recommendation.
Range: 137.23 USD - 181.77 USD (comparables only)
The price implies growth of 10.29% per year; the company grows at 4.22%.
Gross margin 68.3%, net margin 19.7%, ROIC 19.3%, ROE 32.4%.
Net margin
19.70%
Exceptional
Sector 3.88%|S&P 13.40%
Gross margin
68.30%
Exceptional
Return on equity (ROE)
32.39%
Exceptional
Sector 3.46%|S&P 17.06%
Return on invested capital (ROIC)
19.34%
Exceptional
Free cash flow margin (FCF)
23.27%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.18x
High
Margin stability
37.7 pts
Very uneven
Revenue to net income
Growth
5.6/10Revenue up 4.3% over 1 year, 6.0% a year over 5, EPS 4.2% a year over 5.
Revenue (trailing 12 months)
4.5Md USD
Revenue growth (1y)
4.34%
Moderate
Revenue growth (3y)
-5.37%
Declining
EPS growth (1y)
46.67%
Hyper-growth
EPS CAGR (5y)
4.22%
Low
EPS revisions (3 months)
2.33%
Revised up
Valuation
3.6/10P/E 36.0x, forward P/E 41.4x, EV/EBITDA 25.8x, PEG 8.54. The multiple sits in the 42th percentile of its own 5-year history.
P/E (TTM)
36.0x
Fair
Sector 50.5x|S&P 23.6x
Forward P/E
41.4x
Expensive
EV / EBITDA
25.8x
Fair
Sector 22.4x|S&P 15.5x
PEG
8.54
Very expensive
Sector 1.25|S&P 0.91
Fair value (reverse DCF)
159.50 USD
Overvalued
P/E vs its own 5-year history
among the 42% lowest valuations
In line with its history
Market cap
31.7Md USD
Financial strength
4.7/10Cash covers 57.8% of the debt, net debt/EBITDA 0.8x.
Net debt / EBITDA
0.8x
Stretched
Gearing (net debt / equity)
31.03%
Solid
Cash
1.3Md USD
Cash / market cap
4.22%
Tight
Cash / total debt
57.80%
Solid
Interest coverage
9.8x
Solid
Net debt
976M USD
Equity
3.1Md USD
Closed daily candles, 2 years
Last close on November 11, 2026: 212.77 USD
- MM20250.45
- MM50249.39
- MM200178.93
- RSI 1436.7
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+6.73%
200-day average slope, 3 months
+24.17%
50-day average slope, 1 month
+8.52%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
5.34 % per day
Volatility change
+76.50%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 5.06 (8) | 5.48 (20) | 4 630 (19) | 1 319 (7) | 792 (8) |
| 2027 | 5.95 (9) | 6.18 (21) | 4 959 (16) | 1 461 (7) | 914 (8) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 10, 2026.
Same sub-industry: 104 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 603259 | 8.7 | 8.2 | 68.4Md USD | — | — | 70.5 % | — | -1.7x | — | 62.1 % | ||
| 2 | IQV | 7.3 | 6.9 | 45.2Md USD | 33.4x | 8.1 % | 8.0 % | 6.8 % | 4.1x | 4.6 % | 28.0 % | ||
| 3 | A207940 | 7.1 | 7.0 | 52.5Md USD | 39.7x | 41.1 % | -10.2 % | — | -0.2x | — | -24.4 % | ||
| 4 | ILMN | 6.6 | 5.7 | 31.7Md USD | 36.0x | 19.7 % | 4.3 % | 19.3 % | 0.8x | 3.3 % | 70.7 % | ||
| 5 | A | 6.5 | 6.0 | 49.9Md USD | 34.8x | 19.5 % | 8.1 % | 13.9 % | 0.9x | 2.5 % | 20.4 % | ||
| 6 | DHR | 6.5 | 6.4 | 166Md USD | 38.5x | 16.7 % | 8.3 % | 5.9 % | 2.0x | 3.5 % | 11.5 % | ||
| 7 | TMO | 6.2 | 5.5 | 266Md USD | 37.9x | 14.9 % | 9.1 % | 8.0 % | 2.8x | 2.9 % | 24.6 % | ||
| 8 | LONN | 5.6 | 4.7 | 54.1Md USD | Not meaningful (loss) | 16.7 % | 19.2 % | 8.7 % | 1.9x | 0.5 % | 22.7 % | ||
| 9 | WAT | 4.3 | 1.7 | 46.3Md USD | 202.3x | 1.8 % | 120.9 % | 0.8 % | 0.8x | 0.6 % | 23.9 % |
